Pathologic Stage IIIA Gastric Cancer AJCC v8

10 clinical trials · Condition

Record	Firm	Date
Pembrolizumab and Lenvatinib for the Treatment of Advanced, Unresectable, or Metastatic Gastroesophageal Adenocarcinoma (NCT05041153)	M.D. Anderson Cancer Center	2022-02-14
Ramucirumab and Trifluridine/Tipiracil or Paclitaxel for the Treatment of Patients With Previously Treated Advanced Gastric or Gastroesophageal Junction Cancer (NCT04660760)	Academic and Community Cancer Research United	2021-06-16
A Vaccine (Ad5.F35-hGCC-PADRE) for the Treatment of Gastrointestinal Adenocarcinoma (NCT04111172)	Thomas Jefferson University	2020-11-10
Short-Course Chemoradiotherapy Followed by Chemotherapy for the Treatment of Resectable Gastric Adenocarcinoma (NCT04523818)	M.D. Anderson Cancer Center	2020-08-11
Remote Telemonitoring of Patient-Generated Physiologic Health Data and Patient-Reported Outcomes (NCT04501913)	City of Hope Medical Center	2019-12-24
Nivolumab, Ipilimumab and Chemoradiation in Treating Patients With Resectable Gastric Cancer (NCT03776487)	M.D. Anderson Cancer Center	2019-01-07
Early Recovery After Surgery Protocol in Improving Quality of Life in Participants With Stage 0-IIIC Gastric Cancer Undergoing Surgery (NCT03997162)	City of Hope Medical Center	2018-10-11
Pembrolizumab in Treating Patients With Metastatic or Unresectable Gastroesophageal Adenocarcinoma (NCT03395847)	M.D. Anderson Cancer Center	2018-02-09

Every clearance here is in the API, with alerts when new ones post.